Nat Genet:罕见基因突变可防止患II型糖尿病

2014-04-15 佚名 手牵手博客资讯

据美国媒体报道,新发表的一项研究发现,一种罕见的基因突变可以防止人们患上II型糖尿病,可将患病风险降低了三分之二,如此显着的效果为制药公司开辟了一个新的前景:开发一种药物来模仿这种基因突变的效果。据报道,这项新研究是以15万人的基因测试结果为基础进行的。产生胰岛素的胰细胞使用的一个基因遭到这种突变的破坏。有这种基因变异的人产生的胰岛素比正常人略多,一生中的血糖水平都较普通人略低。美国两家公司表示,

据美国媒体报道,新发表的一项研究发现,一种罕见的基因突变可以防止人们患上II型糖尿病,可将患病风险降低了三分之二,如此显着的效果为制药公司开辟了一个新的前景:开发一种药物来模仿这种基因突变的效果。据报道,这项新研究是以15万人的基因测试结果为基础进行的。产生胰岛素的胰细胞使用的一个基因遭到这种突变的破坏。有这种基因变异的人产生的胰岛素比正常人略多,一生中的血糖水平都较普通人略低。

美国两家公司表示,它们已经开始研制效果跟这种突变效果相似的药物了。但公司提醒说,人类遗传学和疾病方面的新发现,可能需要10至20年时间才能转化成可以投放市场的药物。这项研究发布在了《自然-遗传学》(Nature Genetics)上。研究人员说这种突变非常罕见,不久之前人们还无法发现它,这需要使用大量人口的海量数据。

芝加哥大学(University of Chicago)科夫勒糖尿病中心(Kovler Diabetes Center)主任路易斯·菲利普森(Louis Philipson)指出,在糖尿病研究中,这还是第一次出现破坏基因的突变被证实是有益的情况。他说,对于药物研发而言,“这是相当重大的发现。”

现在,研究人员正在调查这种突变是否会对健康产生任何不良影响。研究员斯蒂芬森说,迄今为止还没有发现任何不良影响。根据他掌握的数据,他确定带有这种基因突变的人,患上他搜索的750种其他疾病的可能性并未提高。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685936, encodeId=346d1685936c0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sun Jan 18 11:25:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880012, encodeId=2ca218800125e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Sep 13 00:25:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048582, encodeId=3b5c204858249, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 13 12:25:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945976, encodeId=d6a019459e6eb, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Jun 11 20:25:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733681, encodeId=539b1e3368155, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jul 26 11:25:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429668, encodeId=4eca142966893, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467049, encodeId=c7a0146e0492e, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1685936, encodeId=346d1685936c0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sun Jan 18 11:25:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880012, encodeId=2ca218800125e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Sep 13 00:25:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048582, encodeId=3b5c204858249, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 13 12:25:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945976, encodeId=d6a019459e6eb, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Jun 11 20:25:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733681, encodeId=539b1e3368155, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jul 26 11:25:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429668, encodeId=4eca142966893, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467049, encodeId=c7a0146e0492e, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=)]
    2014-09-13 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1685936, encodeId=346d1685936c0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sun Jan 18 11:25:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880012, encodeId=2ca218800125e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Sep 13 00:25:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048582, encodeId=3b5c204858249, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 13 12:25:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945976, encodeId=d6a019459e6eb, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Jun 11 20:25:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733681, encodeId=539b1e3368155, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jul 26 11:25:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429668, encodeId=4eca142966893, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467049, encodeId=c7a0146e0492e, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=)]
    2014-11-13 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=1685936, encodeId=346d1685936c0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sun Jan 18 11:25:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880012, encodeId=2ca218800125e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Sep 13 00:25:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048582, encodeId=3b5c204858249, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 13 12:25:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945976, encodeId=d6a019459e6eb, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Jun 11 20:25:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733681, encodeId=539b1e3368155, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jul 26 11:25:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429668, encodeId=4eca142966893, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467049, encodeId=c7a0146e0492e, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1685936, encodeId=346d1685936c0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sun Jan 18 11:25:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880012, encodeId=2ca218800125e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Sep 13 00:25:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048582, encodeId=3b5c204858249, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 13 12:25:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945976, encodeId=d6a019459e6eb, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Jun 11 20:25:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733681, encodeId=539b1e3368155, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jul 26 11:25:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429668, encodeId=4eca142966893, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467049, encodeId=c7a0146e0492e, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=)]
    2014-07-26 canlab
  6. [GetPortalCommentsPageByObjectIdResponse(id=1685936, encodeId=346d1685936c0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sun Jan 18 11:25:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880012, encodeId=2ca218800125e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Sep 13 00:25:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048582, encodeId=3b5c204858249, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 13 12:25:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945976, encodeId=d6a019459e6eb, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Jun 11 20:25:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733681, encodeId=539b1e3368155, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jul 26 11:25:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429668, encodeId=4eca142966893, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467049, encodeId=c7a0146e0492e, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1685936, encodeId=346d1685936c0, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sun Jan 18 11:25:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880012, encodeId=2ca218800125e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Sep 13 00:25:00 CST 2014, time=2014-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048582, encodeId=3b5c204858249, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 13 12:25:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945976, encodeId=d6a019459e6eb, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Jun 11 20:25:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733681, encodeId=539b1e3368155, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Jul 26 11:25:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429668, encodeId=4eca142966893, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467049, encodeId=c7a0146e0492e, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Apr 17 00:25:00 CST 2014, time=2014-04-17, status=1, ipAttribution=)]
    2014-04-17 syscxl

相关资讯

IJCP:临床试验表明II型糖尿病药物利拉利汀长期使用有效且安全

利拉利汀(linagliptin)通过阻断二肽基肽酶-4(DPP-4)活性而发挥作用,其中DPP-4一种破坏激素GLP-1的酶,而GLP-1则有助于当需要胰岛素时,身体产生更多的胰岛素。 对II型糖尿病患者开展的一项长期的药物临床试验证实一种口服DPP-4抑制剂利拉利汀是安全的和有效的,这就意味着利用利拉利汀或者与其他选定的口服抗糖尿病药物一起能够降低血糖水平长达102周。 由31个国家参与的

PLoS ONE:A2b型腺苷受体在调节肥胖和II型糖尿病中发挥着重要作用

来自美国波士顿大学医学院的一项研究证实A2b型腺苷受体(A2b-type adenosine receptor, A2bAR)在调节高脂肪和高胆固醇饮食诱导的II型糖尿病症状中发挥着非常重要的作用,而且还鉴定出A2bAR能够作为治疗II型糖尿病的潜在靶标。相关研究发现于2012年7月25日在线发表在PLoS ONE期刊上。 含有高脂肪和高胆固醇的饮食导致身体在调节血糖水平上发生变化。锻炼导致细胞

ADA2013:阿格列汀与二甲双胍联用治疗糖尿病效果好

  一项名为ENSURE(比较阿格列汀与格列吡嗪在与二甲双胍联用两年的疗效与安全性的持久性试验)的研究,近日在第73届美国糖尿病学会年会(ADA)上发布。   该研究历时2年,旨在获得有关阿格列汀在治疗II型糖尿病患者的疗效和安全性方面的新数据。ENDURE研究是一项多中心的随机双盲活性对照研究,由日本武田药品工业株式会社组织多国专家开展,用以评估阿格列汀和格列吡嗪在与二甲双胍联用时,其

Brian Research:GLP-1对老年痴呆症治疗有效

  阿尔斯特大学的科学家们研究发现一种治疗糖尿病的药物有潜力能够治疗神经退行性病变,如阿尔茨海默病。   II型糖尿病是阿尔茨海默病一个已知的危险因素,它破坏大脑内的胰岛素信号传导,这样会损害神经细胞并导致疾病。科学家们相信治疗II型糖尿病的药物同样能够使脑细胞的健康获益。为了证实这一点,科尔雷恩校区生物医学科学研究所的Christian H lscher教授和他的团队使用了一个名为 (Val8

Nature:一种小核糖核酸与Ⅱ型糖尿病有关

英国最新一期《自然》杂志刊登报告说,研究人员发现了一种小核糖核酸与胰岛素耐受性相关,该发现或为开发Ⅱ型糖尿病新疗法提供思路。 德国马克斯·普朗克研究所的研究人员报告说,他们通过动物实验发现,一种名为“miR-802”的小核糖核酸分子在成年实验鼠体内的过度表达会使胰岛素敏感性受损,产生葡萄糖耐受不良,从而与过度肥胖和糖尿病等病症相关。 研究人员延斯·布吕内说,此前研究表明一些小核糖核酸可能会影响

BJC:II型糖尿病的绝经后妇女患乳腺癌风险增加

这项研究是由里昂国际预防研究所(I-PRI)领导实施完成,研究人员归纳分析了40项独立的相关研究的研究结果,以期找出乳腺癌和糖尿病之间的潜在联系。这些研究涉及共超过56000例乳腺癌患者,患者遍布四大洲,结果发现II型糖尿病的绝经后妇女患乳腺癌的风险增加了27%。 患乳腺癌风险的增加似乎只在患有II型糖尿病的绝经后妇女人群中发现,本研究发现II型糖尿病绝经前妇女或I型糖尿病妇女患者发展罹患乳